Recro Pharma has a PEG Value of $3,974.56. A stock is commonly considered to be fairly valued when its PE ratio equals its earnings growth rate. The PEG Value is the price where the PE Ratio, based on next year's earnings estimate, divided by the estimated growth rate over the next couple of years equals 1. This implies that if the company maintains its estimated growth rate, that the stock should gain 23,565.13% in the next year. Among companies with a PEG Value above the current stock price, Recro Pharma is ranked 3.
The StockSelector Value for Recro Pharma is $349.38. The StockSelector Value assumes the market consistently prices a stock around a given PE ratio and, therefore, multiplies the average PE (using forward earnings estimates) over the past three years by future earnings estimates. Among companies with a StockSelector Value above the current stock price, Recro Pharma is ranked 72.
Recro Pharma has a low Put/Call ratio of 0.07 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Recro Pharma is ranked 223.
|90 Day Gain
Recro Pharma rank is 481
|Negative MACD Cross
The MACD Divergence has recently become negative while the MACD remains positive. This is typically a negative short-term indicator.
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Recro Pharma is ranked 641.
|10 Day Loss
Recro Pharma rank is 923
Recro Pharma has a high Put/Call ratio of 0.71 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Recro Pharma is ranked 1565.